Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
35.00
+0.04 (0.11%)
Dec 26, 2024, 4:00 PM EST

Roche Holding AG Company Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions.

It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology.

Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Roche Holding AG
Country Switzerland
Founded 1896
Industry Drug Manufacturers - General
Sector Healthcare
Employees 103,605
CEO Thomas Schinecker

Contact Details

Address:
Grenzacherstrasse 124
Basel, 4058
Switzerland
Phone 41 61 688 11 11
Website roche.com

Stock Details

Ticker Symbol RHHBY
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency CHF
ISIN Number US7711951043
SIC Code 2834

Key Executives

Name Position
Dr. Thomas Schinecker Chief Executive Officer
Dr. Severin Schwan Ph.D. Executive Chairman
Dr. Alan Hippe Chief Financial and Information Officer
Dr. Bruno Eschli Head of Investor Relations
Claudia Bockstiegel General Counsel
Pascale Schmidt Chief Compliance Officer
Barbara Schadler Head of Group Communications
Cristina A. Wilbur Chief People Officer
Dr. Nicolas Dunant Head of Group Media Relations
Boris L. Zaitra Head of Corporate Business Development